Jonathan Zalevsky - 24 Jul 2026 Form 4 Insider Report for NEKTAR THERAPEUTICS (NKTR)

Reporting relationship: Chief R&D Officer
Issuer ticker: NKTR
Reported as of: 24 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 24 Jul 2026, 18:35:04 UTC
Prior SEC filing: 02 Jul 2026
Source filing: View source filing
Reporting owner signature: Elizabeth Zhang, Attorney-in-Fact

Key filing fact

Jonathan Zalevsky filed Form 4 for NEKTAR THERAPEUTICS (NKTR) on 24 Jul 2026.

Key facts

This page summarizes Jonathan Zalevsky's Form 4 filing for NEKTAR THERAPEUTICS (NKTR).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 24 Jul 2026, 18:35.

Change

Previous filing in this sequence was filed on 02 Jul 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001789857 Primary reporting owner

Zalevsky Jonathan

Relationship: Chief R&D Officer
Address: C/O NEKTAR THERAPEUTICS, 455 MISSION BAY BLVD SOUTH, SAN FRANCISCO
Signature: Elizabeth Zhang, Attorney-in-Fact
Signature date: 24 Jul 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NKTR transaction Derivative

Stock Option

Award

Transaction value
Shares: +16,500
Change %
Price: $0.000000^*
Shares after: 16,500
Date: 24 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 16,500
Exercise price: $15.15
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

These stock options were granted on December 13, 2024 under the 2017 Amended and Restated Performance Incentive Plan and at the time of their grant were subject to both performance-based and time-based vesting requirements. The time-based vesting is on a monthly pro-rata basis over a period of five years from the date of grant.

Footnote F2

The Organization and Compensation Committee of the Board of Directors of the Issuer determined on July 23, 2026 that the performance-based vesting requirement for these stock options was satisfied and these stock options vested on July 24, 2026 (subject to remaining time-based vesting requirements).